- Home
- NEWT vs RCKT Comparison
NEWT vs RCKT Comparison
Compare NEWT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWT | RCKT |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.5M | 503.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NEWT | RCKT |
|---|---|---|
| Price | $12.12 | $5.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $14.00 | ★ $29.65 |
| AVG Volume (30 Days) | 163.5K | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.45 | N/A |
| P/E Ratio | $5.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.12 | $2.19 |
| 52 Week High | $14.91 | $8.91 |
Technical Indicators
Market Signals| Indicator | NEWT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 72.16 |
| Support Level | $11.72 | $2.99 |
| Resistance Level | $12.41 | $5.34 |
| Average True Range (ATR) | 0.47 | 0.38 |
| MACD | -0.07 | 0.09 |
| Stochastic Oscillator | 38.99 | 88.33 |
Price Performance
Historical ComparisonAbout NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.